BR112018069931A2 - derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf - Google Patents
derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnfInfo
- Publication number
- BR112018069931A2 BR112018069931A2 BR112018069931A BR112018069931A BR112018069931A2 BR 112018069931 A2 BR112018069931 A2 BR 112018069931A2 BR 112018069931 A BR112018069931 A BR 112018069931A BR 112018069931 A BR112018069931 A BR 112018069931A BR 112018069931 A2 BR112018069931 A2 BR 112018069931A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- modulators
- imidazole derivatives
- fused pentacyclic
- tnf activity
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 150000002460 imidazoles Chemical class 0.000 title abstract 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- MHZUYMLTJORKQU-UHFFFAOYSA-N (3Z)-2H-2,5-benzodiazocin-1-one Chemical class C=1(N=CC=NC=C2C=1C=CC=C2)O MHZUYMLTJORKQU-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000003040 nociceptive effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163572 | 2016-04-01 | ||
| PCT/EP2017/057769 WO2017167996A1 (en) | 2016-04-01 | 2017-03-31 | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018069931A2 true BR112018069931A2 (pt) | 2019-02-05 |
Family
ID=55650322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018069931A BR112018069931A2 (pt) | 2016-04-01 | 2017-03-31 | derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10793578B2 (enExample) |
| EP (1) | EP3436458B1 (enExample) |
| JP (1) | JP6968091B2 (enExample) |
| CN (1) | CN109219608B (enExample) |
| BR (1) | BR112018069931A2 (enExample) |
| CA (1) | CA3018907A1 (enExample) |
| EA (1) | EA201892149A1 (enExample) |
| WO (1) | WO2017167996A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| EP3870586B1 (en) * | 2018-10-24 | 2023-07-05 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| WO2025038927A1 (en) | 2023-08-16 | 2025-02-20 | Raythera, Inc. | Modulators of tnf alpha activity and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006523669A (ja) | 2003-03-10 | 2006-10-19 | ファイザー・インク | Ｎｉｍａ調節タンパク質（ｐｉｎ１）を阻害するための、リン酸／硫酸エステル化合物および医薬組成物 |
| TW200615273A (en) * | 2004-11-10 | 2006-05-16 | Nicholas Piramal India Ltd | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| CN103702994B (zh) | 2011-06-20 | 2016-03-23 | 沃泰克斯药物股份有限公司 | 旋转酶和拓扑异构酶抑制剂的磷酸酯 |
| WO2013186229A1 (en) | 2012-06-11 | 2013-12-19 | Ucb Pharma S.A. | Tnf -alpha modulating benzimidazoles |
| WO2014009295A1 (en) * | 2012-07-13 | 2014-01-16 | Ucb Pharma S.A. | Imidazopyridine derivatives as modulators of tnf activity |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321730D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| CR20170167A (es) | 2014-10-03 | 2017-08-10 | Sanofi Sa | Derivados de imidazol pentacíclicos fusionados |
-
2017
- 2017-03-31 EA EA201892149A patent/EA201892149A1/ru unknown
- 2017-03-31 CN CN201780033366.0A patent/CN109219608B/zh not_active Expired - Fee Related
- 2017-03-31 CA CA3018907A patent/CA3018907A1/en active Pending
- 2017-03-31 US US16/086,311 patent/US10793578B2/en active Active
- 2017-03-31 WO PCT/EP2017/057769 patent/WO2017167996A1/en not_active Ceased
- 2017-03-31 JP JP2018551334A patent/JP6968091B2/ja active Active
- 2017-03-31 EP EP17714243.7A patent/EP3436458B1/en active Active
- 2017-03-31 BR BR112018069931A patent/BR112018069931A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP3436458A1 (en) | 2019-02-06 |
| WO2017167996A1 (en) | 2017-10-05 |
| EP3436458B1 (en) | 2021-06-02 |
| US20190112314A1 (en) | 2019-04-18 |
| JP6968091B2 (ja) | 2021-11-17 |
| US10793578B2 (en) | 2020-10-06 |
| CN109219608B (zh) | 2021-12-21 |
| CA3018907A1 (en) | 2017-10-05 |
| JP2019512534A (ja) | 2019-05-16 |
| EA201892149A1 (ru) | 2019-04-30 |
| CN109219608A (zh) | 2019-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017006669A2 (pt) | derivados de imidazol pentacíclico fundido | |
| BR112016012990A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
| BR112016012997A2 (pt) | Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf | |
| BR112016013012A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
| BR112016012242A2 (pt) | Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf | |
| BR112018069936A2 (pt) | derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf | |
| BR112016011485A2 (pt) | Derivados de imidazopiridazina como moduladores de atividade de tnf | |
| BR112016011484A2 (pt) | Derivados de imidazopirimidina como moduladores de atividade de tnf | |
| EA201500130A1 (ru) | Производные имидазопиридина в качестве модуляторов активности tnf | |
| BR112016011792A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
| BR112018069937A2 (pt) | derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf | |
| BR112016012243A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
| BR112016011483A2 (pt) | Derivados de imidazotriazina como moduladores de atividade de tnf | |
| BR112016012258A2 (pt) | Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf | |
| BR112016012261A2 (pt) | Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf | |
| PH12019502182A1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| BR112016011789A2 (pt) | Derivados de purina, composição farmacêutica compreendendo os mesmos e uso dos mesmos | |
| EA201500133A1 (ru) | Производные имидазопиразина в качестве модуляторов активности tnf | |
| BR112018069931A2 (pt) | derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf | |
| BR112018069941A2 (pt) | derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf | |
| BR112016012253A2 (pt) | Compostos derivados de imidazol e pirazol, composição farmacêutica e uso dos compostos | |
| BR112016013018A2 (pt) | Derivados heteroaromáticos bicíclicos fundidos como moduladores de atividade de tnf | |
| BR112016012254A2 (pt) | Derivados de triazolpiridazina como moduladores de atividade de tnf | |
| BR112014030940A2 (pt) | benzimidazóis que modulam tnf-alfa | |
| BR112016011527A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |